Petersén A - Search Results

1

Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice.

Petersén A, Stewénius Y, Björkqvist M, Gisselsson D. Petersén A, et al. BMC Cell Biol. 2005 Sep 13;6:34. doi: 10.1186/1471-2121-6-34. BMC Cell Biol. 2005. PMID: 16159402 Free PMC article.

2

Recent advances on the pathogenesis of Huntington's disease.

Petersén A, Mani K, Brundin P. Petersén A, et al. Exp Neurol. 1999 May;157(1):1-18. doi: 10.1006/exnr.1998.7006. Exp Neurol. 1999. PMID: 10222105 Review.

3

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.

Hansson O, Petersén A, Leist M, Nicotera P, Castilho RF, Brundin P. Hansson O, et al. Among authors: petersen a. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8727-32. doi: 10.1073/pnas.96.15.8727. Proc Natl Acad Sci U S A. 1999. PMID: 10411943 Free PMC article.

4

Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.

Petersén A, Hansson O, Puschban Z, Sapp E, Romero N, Castilho RF, Sulzer D, Rice M, DiFiglia M, Przedborski S, Brundin P. Petersén A, et al. Eur J Neurosci. 2001 Nov;14(9):1425-35. doi: 10.1046/j.0953-816x.2001.01765.x. Eur J Neurosci. 2001. PMID: 11722604

5

Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.

Petersén A, Chase K, Puschban Z, DiFiglia M, Brundin P, Aronin N. Petersén A, et al. Exp Neurol. 2002 May;175(1):297-300. doi: 10.1006/exnr.2002.7885. Exp Neurol. 2002. PMID: 12009780

6

Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.

Petersén A, Puschban Z, Lotharius J, NicNiocaill B, Wiekop P, O'Connor WT, Brundin P. Petersén A, et al. Neurobiol Dis. 2002 Oct;11(1):134-46. doi: 10.1006/nbdi.2002.0534. Neurobiol Dis. 2002. PMID: 12460553

7

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.

Gil JM, Leist M, Popovic N, Brundin P, Petersén A. Gil JM, et al. Among authors: petersen a. BMC Neurosci. 2004 May 10;5:17. doi: 10.1186/1471-2202-5-17. BMC Neurosci. 2004. PMID: 15134587 Free PMC article.

8

Orexin loss in Huntington's disease.

Petersén A, Gil J, Maat-Schieman ML, Björkqvist M, Tanila H, Araújo IM, Smith R, Popovic N, Wierup N, Norlén P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P. Petersén A, et al. Hum Mol Genet. 2005 Jan 1;14(1):39-47. doi: 10.1093/hmg/ddi004. Epub 2004 Nov 3. Hum Mol Genet. 2005. PMID: 15525658

9

The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis.

Björkqvist M, Fex M, Renström E, Wierup N, Petersén A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H. Björkqvist M, et al. Among authors: petersen a. Hum Mol Genet. 2005 Mar 1;14(5):565-74. doi: 10.1093/hmg/ddi053. Epub 2005 Jan 13. Hum Mol Genet. 2005. PMID: 15649949

10

Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.

Gil JM, Mohapel P, Araújo IM, Popovic N, Li JY, Brundin P, Petersén A. Gil JM, et al. Among authors: petersen a. Neurobiol Dis. 2005 Dec;20(3):744-51. doi: 10.1016/j.nbd.2005.05.006. Epub 2005 Jun 13. Neurobiol Dis. 2005. PMID: 15951191

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,818 results

Search Page

Filters